Evaluation of mavacamten in patients with hypertrophic cardiomyopathy.
J Cardiovasc Med (Hagerstown)
; 25(7): 491-498, 2024 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-38814051
ABSTRACT
AIMS:
We aimed to comprehensively assess the safety and efficacy of mavacamten in hypertrophic cardiomyopathy (HCM) patients.METHODS:
A systematic review and meta-analysis was conducted, and efficacy [changes in postexercise left ventricular outflow tract (LVOT) gradient, left ventricular ejection fraction (LVEF), peak oxygen consumption (pVO 2 ), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS), and the proportion of patients exhibiting an improvement of at least one New York Heart Association (NYHA) functional class from baseline)], safety (total count of treatment-emergent adverse events and SAEs, as well as the proportion of patients experiencing at least one adverse event or SAE), and cardiac biomarkers (NT-proBNP and cTnI) outcomes were evaluated.RESULTS:
We incorporated data from four randomized controlled trials, namely EXPLORER-HCM, VALOR-HCM, MAVERICK-HCM, and EXPLORER-CN. Mavacamten demonstrated significant efficacy in reducing the postexercise LVOT gradient by 49.44âmmHg ( P â=â0.0001) and LVEF by 3.84 ( P â<â0.0001) and improving pVO 2 by 0.69âml/kg/min ( P â=â0.4547), KCCQ CSS by 8.11 points ( P â<â0.0001), and patients with at least one NYHA functional class improvement from baseline by 2.20 times ( P â<â0.0001). Importantly, mavacamten increased 1.11-fold adverse events ( P â=â0.0184) 4.24-fold reduced LVEF to less than 50% ( P â=â0.0233) and 1.06-fold SAEs ( P â=â0.8631). Additionally, mavacamten decreased NT-proBNP by 528.62âng/l ( P â<â0.0001) and cTnI by 8.28âng/l ( P â<â0.0001).CONCLUSION:
Mavacamten demonstrates both safety and efficacy in patients with HCM, suggesting its potential as a promising therapeutic strategy for this condition. Further research is warranted to confirm these results and explore its long-term effects.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cardiomiopatia Hipertrófica
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Função Ventricular Esquerda
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Cardiovasc Med (Hagerstown)
Assunto da revista:
ANGIOLOGIA
/
CARDIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Estados Unidos